Literature DB >> 8093033

Purification and molecular cloning of human apolipoprotein F.

J R Day1, J J Albers, T L Gilbert, T E Whitmore, W J McConathy, G Wolfbauer.   

Abstract

In our effort to study proteins that are involved in high density lipoprotein metabolism, we have identified apolipoprotein F and isolated a full length cDNA clone. Apolipoprotein F, with an apparent molecular mass of 29 kilodaltons, was purified from human high density lipoproteins using a modified two dimensional electrophoresis procedure. The cDNA, with a size of 1735 base pairs, was cloned from a Hep G2 cDNA library. The cDNA encodes apolipoprotein F, which is composed of 162 amino acids, and predicts that apolipoprotein F is a proteolytic product of a larger protein. Northern blot analysis indicates that apolipoprotein F mRNA is detected only in liver for the tissues examined. The gene was mapped to human chromosome number 12 using a human/rodent somatic cell hybrid mapping panel.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8093033     DOI: 10.1006/bbrc.1994.2302

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism.

Authors:  Yan Liu; Richard E Morton
Journal:  Curr Opin Lipidol       Date:  2020-08       Impact factor: 4.776

2.  Genetic control of a mouse serum lipoprotein factor that inactivates murine leukemia viruses: evaluation of apolipoprotein F as a candidate.

Authors:  Tiyun Wu; Chun G Lee; Alicia Buckler-White; Christine A Kozak
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis.

Authors:  William R Lagor; David W Fields; Robert C Bauer; Alison Crawford; Michael C Abt; David Artis; E John Wherry; Daniel J Rader
Journal:  Atherosclerosis       Date:  2014-01-10       Impact factor: 5.162

4.  Control of cholesteryl ester transfer protein activity by sequestration of lipid transfer inhibitor protein in an inactive complex.

Authors:  Yubin He; Diane J Greene; Michael Kinter; Richard E Morton
Journal:  J Lipid Res       Date:  2008-03-27       Impact factor: 5.922

5.  Altered expression of genes functioning in lipid homeostasis is associated with lipid deposition in NOD mouse lacrimal gland.

Authors:  Kaijin Wu; Corrine Joffre; Xiaodong Li; Michelle MacVeigh-Aloni; Melinda Hom; Juliana Hwang; Chuanqing Ding; Stephane Gregoire; Lionel Bretillon; Jiang F Zhong; Sarah F Hamm-Alvarez
Journal:  Exp Eye Res       Date:  2009-04-02       Impact factor: 3.467

6.  Network analysis in the identification of special mechanisms between small cell lung cancer and non-small cell lung cancer.

Authors:  Weisan Zhang; Qiang Zhang; Mingpeng Zhang; Yun Zhang; Fengtan Li; Ping Lei
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

7.  Molecular cloning of hamster lipid transfer inhibitor protein (apolipoprotein F) and regulation of its expression by hyperlipidemia.

Authors:  Lahoucine Izem; Richard E Morton
Journal:  J Lipid Res       Date:  2008-11-13       Impact factor: 5.922

8.  Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo.

Authors:  William R Lagor; Robert J Brown; Sue-Anne Toh; John S Millar; Ilia V Fuki; Margarita de la Llera-Moya; Tiffany Yuen; George Rothblat; Jeffrey T Billheimer; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-13       Impact factor: 8.311

9.  The effects of apolipoprotein F deficiency on high density lipoprotein cholesterol metabolism in mice.

Authors:  William R Lagor; David W Fields; Sumeet A Khetarpal; Arthi Kumaravel; Wen Lin; Nathaniel Weintraub; Kaijin Wu; Sarah F Hamm-Alvarez; Denise Drazul-Schrader; Margarita de la Llera-Moya; George H Rothblat; Daniel J Rader
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

10.  Apolipoprotein F concentration, activity, and the properties of LDL controlling ApoF activation in hyperlipidemic plasma.

Authors:  Richard E Morton; Daniel Mihna
Journal:  J Lipid Res       Date:  2022-01-08       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.